Press release: Umeå, 27 September, 2022. Lipum AB (publ) announces today that the CTA (clinical trial application) for the drug candidate SOL-116 has been approved by the regulatory authorities in The Netherlands.

The study that includes healthy volunteers and patients with rheumatoid arthritis will be carried out at QPS BV facility in Groningen, Netherlands. The study will be conducted as a dose escalation study by beginning with a very low dose and then gradually increasing the dose. The study is planned to start in October.

“As planned, the clinical trial application has been approved and thus a very important milestone has been reached when Lipum has manage to go from preclinical to clinal development for our drug candidate SOL-116. I´m very proud of the team and everyone who has contributed to this success with great dedication", says Einar Pontén, CEO of Lipum.

For further information, please contact:
Einar Pontén, CEO
Mobile:   +46 70 578 34 95

About Lipum

Lipum AB (publ) is a biopharmaceutical company specialized in discovery and development of a novel treatment for chronic inflammatory diseases. The lead candidate SOL-116 is a humanized antibody designed to provide efficacious therapy by blocking a previously overlooked target molecule of the immune system (BSSL). SOL-116 is in late preclinical stage supported by solid data for rheumatoid arthritis. Lipum also explores other inflammatory diseases with a high unmet medical need. The company is based in Umeå, an excellent life science cluster in Sweden. Lipum’s unique approach has attracted international attention, including a major European Commission Horizon 2020 grant. The company's share (LIPUM) is traded on the Nasdaq First North Growth Market. Certified Adviser is G&W Fondkommission.